NDAINTRACAVITARY, INTRAVENOUS, INTRAVESICALPOWDER
Approved
Jan 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
5/8 — Partial
TEPADINA (thiotepa) by Adienne Pharma and Biotech is alkylating activity [moa]. Approved for brain and central nervous system tumors, acute myeloid leukemia, myelodysplastic syndromes. First approved in 2017.
Drug data last refreshed 19h ago
Mechanism of Action
Alkylating Activity
Pharmacologic Class:
Alkylating Drug
Worked on TEPADINA at Adienne Pharma and Biotech? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.